Cornelia Kolberg‐Liedtke

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

Oleg Gluz, Cornelia Kolberg‐Liedtke, Aleix Prat et al. · International Journal of Cancer · 2019 · 51 citations

Medicine, Oncology, Pharmacology +17

CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis

Carolin Müller, Verena Kiver, Erich‐Franz Solomayer et al. · Breast Care · 2022 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/<i>ERBB2</i>-Positive Early Breast Cancer

Oleg Gluz, Ulrike Nitz, Matthias Christgen et al. · JAMA Oncology · 2023 · 36 citations · Full text

Medicine, Oncology, Pharmacology +17

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

Nadia Harbeck, Ulrike Nitz, Matthias Christgen et al. · Journal of Clinical Oncology · 2023 · 35 citations

Medicine, Oncology, Pharmacotherapy +17

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

Monika Graeser, Friedrich Feuerhake, Oleg Gluz et al. · Journal for ImmunoTherapy of Cancer · 2021 · 27 citations · Full text

Medicine, Immunology, Oncology +17